Roche Holding AG Bearer Shares RHHBF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Roche Confirms Narrowed Pharma Focus, Fast Tracks Obesity-Drug Candidate — Update
-
Roche Confirms Narrowed Pharma Focus, Fast Tracks Obesity-Drug Candidate
-
Regor to Sell Breast Cancer CDK Inhibitors to Roche Unit for Upfront $850 Million
-
Roche's Cancer Drug Candidate Shows Positive Results in Late Stage Trial
-
Roche Says Xofluza Achieved Positive Results in Phase 3 Influenza Trial
-
Roche Gets FDA Approval for Multiple-Sclerosis Treatment
-
Genentech Receives FDA Approval for Cancer Treatment
-
Genentech receives FDA approval for cancer treatment
Trading Information
- Previous Close Price
- $317.25
- Day Range
- $308.47–340.33
- 52-Week Range
- $243.42–368.43
- Bid/Ask
- $315.00 / $374.37
- Market Cap
- $266.92 Bil
- Volume/Avg
- 24 / 80
Key Statistics
- Price/Earnings (Normalized)
- 14.90
- Price/Sales
- 3.94
- Dividend Yield (Trailing)
- 3.24%
- Dividend Yield (Forward)
- 3.24%
- Total Yield
- 3.24%
Company Profile
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Large Core
- Total Number of Employees
- 103,605
- Website
- https://www.roche.com
Competitors
Valuation
|
Metric
|
RHHBF
|
MRK
|
ABBV
|
|---|---|---|---|
Price/Earnings (Normalized) | 14.90 | 16.86 | 18.16 |
Price/Book Value | 8.29 | 6.39 | 50.62 |
Price/Sales | 3.94 | 4.48 | 6.26 |
Price/Cash Flow | 14.39 | 14.92 | 18.43 |
Price/Earnings
RHHBF
MRK
ABBV
Financial Strength
|
Metric
|
RHHBF
|
MRK
|
ABBV
|
|---|---|---|---|
Quick Ratio | 0.80 | 0.88 | 0.59 |
Current Ratio | 1.26 | 1.47 | 0.81 |
Interest Coverage | 11.62 | 13.07 | 3.51 |
Quick Ratio
RHHBF
MRK
ABBV
Profitability
|
Metric
|
RHHBF
|
MRK
|
ABBV
|
|---|---|---|---|
Return on Assets (Normalized) | 16.64% | 15.46% | 13.66% |
Return on Equity (Normalized) | 53.11% | 41.15% | 189.99% |
Return on Invested Capital (Normalized) | 25.43% | 22.92% | 27.06% |
Return on Assets
RHHBF
MRK
ABBV
Drug Manufacturers - General Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| Hcsdxtchy | Crrd | $798.8 Bil | |||
| Johnson & Johnson
JNJ
| Xbfjtnmf | Wxkc | $385.9 Bil | |||
| AbbVie Inc
ABBV
| Kjmxpvzvx | Lss | $343.2 Bil | |||
| Merck & Co Inc
MRK
| Pvdsxcxv | Jzj | $278.2 Bil | |||
| Roche Holding AG ADR
RHHBY
| Zpqlnhpsp | Vcqm | $244.4 Bil | |||
| AstraZeneca PLC ADR
AZN
| Tlcltfdgfp | Bjs | $238.9 Bil | |||
| Novartis AG ADR
NVS
| Ybcrhldd | Rpxj | $232.2 Bil | |||
| Amgen Inc
AMGN
| Srbgjhcpv | Bnsfc | $171.8 Bil | |||
| Pfizer Inc
PFE
| Khzvhppwq | Yhjh | $162.0 Bil | |||
| Sanofi SA ADR
SNY
| Yjhlspdl | Gyfkb | $140.7 Bil |
United States